Unknown

Dataset Information

0

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.


ABSTRACT: The hepatocyte-specific asialoglycoprotein receptor (ASGPR) is an ideal candidate for targeted drug delivery to the liver due to its high capacity for substrate clearance from circulation together with its well-conserved expression and function across species. The development of GalNAc-siRNA conjugates, in which a synthetic triantennary N-acetylgalactosamine-based ligand is conjugated to chemically modified siRNA, has enabled efficient, ASGPR-mediated delivery to hepatocytes. To investigate the potential impact of variations in receptor expression on the efficiency of GalNAc-siRNA conjugate delivery, we evaluated the pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates in multiple pre-clinical models with reduced receptor expression. Despite greater than 50% reduction in ASGPR levels, GalNAc conjugate activity was retained, suggesting that the remaining receptor capacity was sufficient to mediate efficient uptake of potent GalNAc-siRNAs at pharmacologically relevant dose levels. Collectively, our data support a broad application of the GalNAc-siRNA technology for hepatic targeting, including disease states where ASGPR expression may be reduced.

SUBMITTER: Willoughby JLS 

PROVIDER: S-EPMC5762979 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2018-05-02 | GSE110620 | GEO
| S-EPMC5363199 | biostudies-literature
| S-EPMC10609014 | biostudies-literature
| S-EPMC9181004 | biostudies-literature
| S-EPMC5389643 | biostudies-literature
| S-EPMC6453860 | biostudies-literature
2017-09-21 | GSE104031 | GEO
| S-EPMC6468299 | biostudies-literature
| S-EPMC2996795 | biostudies-literature